W1M Asset Management Ltd Buys Shares of 10,700 Arrowhead Pharmaceuticals, Inc. $ARWR

W1M Asset Management Ltd purchased a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,700 shares of the biotechnology company’s stock, valued at approximately $873,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Landscape Capital Management L.L.C. bought a new position in shares of Arrowhead Pharmaceuticals during the second quarter valued at $2,089,000. EP Wealth Advisors LLC bought a new position in Arrowhead Pharmaceuticals during the 2nd quarter valued at about $3,108,000. Allworth Financial LP bought a new position in Arrowhead Pharmaceuticals during the 2nd quarter valued at about $49,000. B. Metzler seel. Sohn & Co. AG purchased a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at about $2,147,000. Finally, Virtus Advisers LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the second quarter worth approximately $754,000. 62.61% of the stock is owned by institutional investors.

Arrowhead Pharmaceuticals Stock Down 0.4%

Shares of ARWR stock opened at $87.11 on Friday. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $20.44 and a 12 month high of $95.49. The stock has a market cap of $12.27 billion, a P/E ratio of -38.72 and a beta of 1.27. The company has a 50 day simple moving average of $82.84 and a two-hundred day simple moving average of $72.87.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.13). The business had revenue of $75.25 million for the quarter, compared to analysts’ expectations of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The company’s revenue was up 171.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.26) EPS. On average, research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on ARWR shares. B. Riley Financial increased their price objective on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Leerink Partners boosted their target price on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a research note on Wednesday, June 17th. Sanford C. Bernstein increased their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. Wall Street Zen raised Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Finally, Royal Bank Of Canada upped their price objective on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $97.33.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, Director Michael S. Perry sold 11,600 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the transaction, the director directly owned 111,459 shares of the company’s stock, valued at $9,730,370.70. The trade was a 9.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Adeoye Y. Olukotun sold 2,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the transaction, the director directly owned 31,600 shares in the company, valued at approximately $2,747,936. The trade was a 5.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.60% of the stock is currently owned by insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.